Khoa Nguyen, MD
Family Medicine · Houston, TXNPI 1437146966
Payments from drug & device makers
Across 159 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$411
- Teva Pharmaceuticals USA, Inc.$373
- Sunovion Pharmaceuticals Inc.$318
- Sumitomo Pharma America, Inc.$109
- Exact Sciences$88
- Eisai Inc.$85
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,521100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 22 | $411 |
| Teva Pharmaceuticals USA, Inc. | 24 | $373 |
| Sunovion Pharmaceuticals Inc. | 36 | $318 |
| Sumitomo Pharma America, Inc. | 10 | $109 |
| Exact Sciences | 4 | $88 |
| Eisai Inc. | 4 | $85 |
| Novartis | 5 | $83 |
| AstraZeneca | 4 | $75 |
| Johnson & Johnson(2 entities) | 5 | $74 |
| Medtronic(2 entities) | 4 | $71 |
| Pfizer | 4 | $65 |
| Abbott | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Redhill Biopharma Inc. | 3 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $53 |
| Alkermes, Inc. | 2 | $47 |
| Urovant Sciences Inc | 2 | $44 |
| Gilead | 2 | $39 |
| GSK | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Philips North America LLC | 2 | $31 |
| Novo Nordisk | 1 | $26 |
| Optinose US, Inc. | 1 | $26 |
| Corium, LLC | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Amgen | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$2,521 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $97,420 |
| OzempicSemaglutide | 81 | $89,200 |
| EliquisApixaban | 224 | $88,557 |
| VascepaIcosapent Ethyl | 202 | $85,534 |
| TrulicityDulaglutide | 44 | $45,267 |
| JanuviaSitagliptin Phosphate | 42 | $34,703 |
| JardianceEmpagliflozin | 39 | $34,050 |
| IngrezzaValbenazine Tosylate | 13 | $34,028 |
| MyrbetriqMirabegron | 106 | $32,394 |
| EntrestoSacubitril/Valsartan | 43 | $31,394 |
| XareltoRivaroxaban | 104 | $29,552 |
| AptiomEslicarbazepine Acetate | 34 | $22,928 |
| TradjentaLinagliptin | 27 | $15,399 |
| FarxigaDapagliflozin Propanediol | 32 | $12,636 |
| RestasisCyclosporine | 24 | $12,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $65 | $94,837244 claims |
| Novo NordiskOzempic | $26 | $89,20081 claims |
| Lilly USA, LLCTrulicity | $35 | $45,26744 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $32,394106 claims |
| NovartisEntresto | $83 | $31,39443 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $75 | $29,882107 claims |
| Johnson & JohnsonXarelto | $74 | $29,552104 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $318 | $22,92834 claims |
| GSKBreo Ellipta, Incruse Ellipta | $37 | $16,50342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.